{"pmid":32360327,"title":"Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence.","text":["Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence.","Travel Med Infect Dis","Khambholja, Kapil","Asudani, Deepak","32360327"],"journal":"Travel Med Infect Dis","authors":["Khambholja, Kapil","Asudani, Deepak"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360327","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.tmaid.2020.101710","e_drugs":["favipiravir"],"topics":["Treatment"],"weight":1,"_version_":1666138495499894786,"score":9.490897,"similar":[{"pmid":32401463,"title":"Favipiravir","text":["Favipiravir","Favipiravir is an investigational antiviral drug that is being tested for use against the novel coronavirus disease, COVID-19. No information is available on the use of favipiravir during breastfeeding or its excretion into breastmilk. Favipiravir is a small molecule that is about 60% protein bound in plasma, so it would be expected to appear in breastmilk and be absorbed by the infant, probably in small amounts. In clinical trials, favipiravir has been well tolerated, but has caused liver enzyme abnormalities, gastrointestinal symptoms, and serum uric acid elevations.[1-3] If favipiravir is used in a nursing mother, these parameters should be monitored in the breastfed infant.","Drugs and Lactation Database (LactMed)","32401463"],"abstract":["Favipiravir is an investigational antiviral drug that is being tested for use against the novel coronavirus disease, COVID-19. No information is available on the use of favipiravir during breastfeeding or its excretion into breastmilk. Favipiravir is a small molecule that is about 60% protein bound in plasma, so it would be expected to appear in breastmilk and be absorbed by the infant, probably in small amounts. In clinical trials, favipiravir has been well tolerated, but has caused liver enzyme abnormalities, gastrointestinal symptoms, and serum uric acid elevations.[1-3] If favipiravir is used in a nursing mother, these parameters should be monitored in the breastfed infant."],"journal":"Drugs and Lactation Database (LactMed)","date":"2020-05-14T11:01:00Z","year":2006,"_id":"32401463","source":"PubMed","week":"202020|May 11 - May 17","keywords":["favipiravir","avigan","6-fluoro-3-hydroxy-2-pyrazinecarboxamide","t 705","t-705","t705","unii-ew5gl2x7e0","5-fluoro-2-oxo-1h-pyrazine-3-carboxamide","2-pyrazinecarboxamide, 6-fluoro-3-hydroxy-"],"topics":["Treatment"],"weight":1,"_version_":1666714494907187200,"score":43.98191}]}